Write in a clean editor, then format for Neuro-Oncology Advances in one click — DocuGuru applies the official Oxford University Press template with author–year references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Neuro-Oncology Advances is a peer-reviewed journal published by Oxford University Press, covering Glioma Diagnosis and Treatment, Brain Metastases and Treatment, Meningioma and schwannoma management.
| Publisher | Oxford University Press |
|---|---|
| Reference style | Author–year (OUP) Author–year — (Smith, 2023) in the text Smith, A., Jones, B. and Lee, C. (2023) 'A representative article title', Neuro-Oncology Advances, 12(3), pp. 45–58.
Formats any DOI in the closest standard style — Neuro-Oncology Advances has no published style definition, so this is an approximation. No sign-up. |
| Publishes research in | Glioma Diagnosis and Treatment Brain Metastases and Treatment Meningioma and schwannoma management Radiomics and Machine Learning in Medical Imaging Neurofibromatosis and Schwannoma Cases |
| ISSN | 2632-2498 |
| Citation impact (2-yr) | 1.08 |
| h-index | 50 |
| i10-index | 478 |
| Total citations | 15,902 |
| Article processing charge | $1,989 |
| Open access | Yes |
| Top institutions publishing here | Neurological Surgery |
| Journal website | academic.oup.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Glioblastoma (GBM) tumor microenvironment (TME) is a highly heterogeneous and complex system, which in addition to cancer cells, consists of various resident brain and immune cells as well as cells in transit through the tumor such as marrow-derived immune cells. The TME is a dynamic environment which is heavily influenced by alterations in cellular composition,…
Glioblastoma (GBM) is an incurable brain tumor with a median survival of approximately 15 months despite an aggressive standard of care that includes surgery, chemotherapy, and ionizing radiation. Mouse models have advanced our understanding of GBM biology and the development of novel therapeutic strategies for GBM patients. However, model selection is crucial when testing developmental…
Continued improvements in cancer therapies have increased the number of long-term cancer survivors. Radiation therapy remains one of the primary treatment modalities with about 60% of newly diagnosed cancer patients receiving radiation during the course of their disease. While radiation therapy has dramatically improved patient survival in a number of cancer types, the late effects…
Over the past decades, a variety of PET tracers have been used for the evaluation of patients with brain tumors. For clinical routine, the most important clinical indications for PET imaging in patients with brain tumors are the identification of neoplastic tissue including the delineation of tumor extent for the further diagnostic and therapeutic management…
Abstract Background “Diffuse midline glioma (DMG), H3 K27M-mutant” is a new tumor entity established in the 2016 WHO classification of Tumors of the Central Nervous System that comprises a set of diffuse gliomas arising in midline structures and is molecularly defined by a K27M mutation in genes encoding the histone 3 variants H3.3 or H3.1.…
